ADVISORY, Nov. 14, 2016 (GLOBE NEWSWIRE) --
What: Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN ), a science-driven, patient-focused company seeking to leverage its strengths across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Dr. Milind S. Deshpande, President and Chief Executive Officer , will ring the Closing Bell.
Where: Nasdaq MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio
When: Tuesday, November 15, 2016 – 3:45 p.m. to 4:00 p.m. ET
Achillion Pharmaceuticals, Inc. Contact: Liz Power 203 752 5509 Lpower@achillion.com
Nasdaq MarketSite: Emily Pan (646) 441-5120 emily.pan@nasdaq.com
Feed Information: Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page: http://www.facebook.com/NASDAQ
For photos from ceremonies and events, please visit our Instagram page: http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our YouTube page: http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page: http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our Tumblr page: http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.
About Achillion Pharmaceuticals Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN ) is a science-driven, patient-focused company seeking to leverage its strengths across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to pursue best-in-class oral antiviral therapy for chronic hepatitis C (HCV) and build a platform of potent and specific complement inhibitors. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases. More information is available at http://www.achillion.com
About Nasdaq Nasdaq (Nasdaq: NDAQ ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of $10 trillion and approximately 18,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com
-NDAQA-
